Skip to main content

Table 1 The criteria for improvements in facial angiofibroma lesions from baseline

From: Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex

Rating

Size

Color

Improved

Reduced in ≥50% of lesions

Improved by ≥2 reddishness levels in ≥50% of lesions

Unchanged

Not obviously changed

Not obviously changed

Aggravated

Increased or newly formed papules in ≥50% of lesions

Aggravated by ≥2 reddishness levels in ≥50% of lesions